1. Home
  2. PROK vs BOC Comparison

PROK vs BOC Comparison

Compare PROK & BOC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • PROK
  • BOC
  • Stock Information
  • Founded
  • PROK 2015
  • BOC 2009
  • Country
  • PROK United States
  • BOC United States
  • Employees
  • PROK N/A
  • BOC N/A
  • Industry
  • PROK Biotechnology: Biological Products (No Diagnostic Substances)
  • BOC
  • Sector
  • PROK Health Care
  • BOC
  • Exchange
  • PROK Nasdaq
  • BOC Nasdaq
  • Market Cap
  • PROK 417.1M
  • BOC 413.9M
  • IPO Year
  • PROK N/A
  • BOC 2017
  • Fundamental
  • Price
  • PROK $2.97
  • BOC $13.78
  • Analyst Decision
  • PROK Strong Buy
  • BOC Strong Buy
  • Analyst Count
  • PROK 4
  • BOC 1
  • Target Price
  • PROK $6.25
  • BOC $25.00
  • AVG Volume (30 Days)
  • PROK 2.1M
  • BOC 164.9K
  • Earning Date
  • PROK 11-11-2025
  • BOC 11-11-2025
  • Dividend Yield
  • PROK N/A
  • BOC N/A
  • EPS Growth
  • PROK N/A
  • BOC N/A
  • EPS
  • PROK N/A
  • BOC 0.02
  • Revenue
  • PROK $527,000.00
  • BOC $111,568,551.00
  • Revenue This Year
  • PROK $427.89
  • BOC $7.79
  • Revenue Next Year
  • PROK N/A
  • BOC $3.80
  • P/E Ratio
  • PROK N/A
  • BOC $665.48
  • Revenue Growth
  • PROK N/A
  • BOC 9.53
  • 52 Week Low
  • PROK $0.46
  • BOC $12.27
  • 52 Week High
  • PROK $7.13
  • BOC $16.20
  • Technical
  • Relative Strength Index (RSI)
  • PROK 55.05
  • BOC 58.06
  • Support Level
  • PROK $2.80
  • BOC $13.80
  • Resistance Level
  • PROK $3.28
  • BOC $14.23
  • Average True Range (ATR)
  • PROK 0.27
  • BOC 0.34
  • MACD
  • PROK 0.01
  • BOC 0.07
  • Stochastic Oscillator
  • PROK 57.52
  • BOC 63.38

About PROK ProKidney Corp.

ProKidney Corp is a clinical-stage biotechnology company with a transformative proprietary cell therapy platform capable of treating multiple chronic kidney diseases using a patient's cells isolated from the patient intended for treatment. Its product candidate, REACT (Renal Autologous Cell Therapy) is a disease-modifying cell therapy made from a patient's renal cells. REACT has the potential to slow and stabilize the progression of chronic kidney disease. The company's pipeline consists of the development program for severe diabetic kidney disease.

About BOC Boston Omaha Corporation

Boston Omaha Corp is a United States based company which invests in real estate. Its operations include its ownership of multiple billboards in Florida, Georgia, Wisconsin, and Alabama and equity method investments in several real estate companies. The company operates four separate lines of business, outdoor billboard advertising, the broadband services industry, the insurance industry, and the asset management industry. Company generate revenue from outdoor advertising through the leasing of advertising space on billboards. It also generate revenue from commissions on surety bond sales and account for commissions and principally from internet services and is recognized on a straight-line basis over the term of the contract in the period the services are rendered.

Share on Social Networks: